written on 11.04.2014
Tags:
,

BMS hep C combo good, but is it good enough?

TAGS: ,

In the EU, the European Medicines Agency validated BMS's marketing authorization application in January for the use of daclatasvir in combination with other agents to treat adults with HCV with compensated liver disease, including genotypes 1, 2, 3, and…

Latest Report